Are you Dr. Patnaik?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 69 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
200 1st St SW
Rochester, MN 55905Phone+1 507-284-2511Fax+1 507-255-3125
Summary
- Dr. Mrinal Patnaik, MD is an oncologist in Rochester, Minnesota. He is currently licensed to practice medicine in Minnesota. He is affiliated with Mayo Clinic Hospital - Rochester.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2008 - 2011
University of MinnesotaResidency, Internal Medicine, 2005 - 2008
Grant Medical CollegeClass of 2000
Certifications & Licensure
MN State Medical License 2007 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
- Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Start of enrollment: 2013 Dec 24
- A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL Start of enrollment: 2015 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 9 citationsDeletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience.Rama Nanah, Darci Zblewski, Mrinal S. Patnaik, Kebede H. Begna, Rhett P. Ketterling
Leukemia Research. 2016-11-01 - 42 citationsA phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)Farhad Ravandi, Ivana Gojo, Mrinal M. Patnaik, Mark D. Minden, Hagop M. Kantarjian
Leukemia Research. 2016-09-01 - 46 citationsRAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic featuresGiacomo Coltro, Giada Rotunno, Lara Mannelli, Carmela Mannarelli, Sara Fiaccabrino
Blood Advances. 2020-08-11
Press Mentions
- Mayo Clinic Physician Cracks Patient’s Mysterious Illness with Epigenetics TechnologyMarch 10th, 2021
